ArticleJournal of neurology2026
Nociceptive pain in late-onset Pompe disease: prevalence, distribution, and clinical correlates.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundNociceptive pain is often recognized as a relevant symptom in late-onset Pompe disease (LOPD), yet its prevalence, distribution, and underlying determinants remain insufficiently characterized. We aimed to systematically assess nociceptive pain in LOPD and to explore its relationship with muscle function, structural muscle alterations, and potential modifiers.
methodsIn this multicenter cross-sectional study, 42 patients with LOPD and 61 disease controls (IBM, FSHD, SMA3) were evaluated. Pain was assessed using validated questionnaires and pain drawings. Motor function tests, pressure pain thresholds, muscle ultrasound, laboratory parameters, and genetic polymorphisms (ACE, ACTN3) were obtained. Associations between pain and clinical, structural, and biological variables were analyzed.
resultsChronic nociceptive musculoskeletal pain was highly prevalent, particularly in LOPD (83.3%) compared to disease controls (p=0.005). However, pain reported on the assessment day was significantly lower in LOPD (30.9%, p<0.001) and SMA3 (25%, p=0.016). No significant associations were found between pain and muscle strength, motor function tests, ultrasound-detected muscle alterations, ACTN3 and ACE, and laboratory parameters.
conclusionMusculoskeletal pain is highly prevalent in LOPD but remains dissociated from objective measures of motor impairment, structural changes of muscle tissue, or genetic modifiers. The significant discrepancy between chronic pain history and acute pain reporting particularly in LOPD and SMA3 suggests that pain represents an independent clinical domain that is not fully captured by single-point assessments. Clinical management should focus on individualized pain assessment, as standard functional tests and snapshot pain assessments do not adequately reflect the patient's pain burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.